Accord Healthcare Recalls 20 Different Medications

Accord Healthcare Inc is recalling a multitude of medications distributed in the United States, Puerto Rico, and Canada, according to the March 8, 2023, US Food and Drug Administration (FDA) Enforcement Report. The report cites deviations from Current Good Manufacturing Practices identified during an FDA inspection, but provides no other information.

The recall affects the following products, which were manufactured by Intas Pharmaceuticals Limited, Ahmedabad, India, for Accord Healthcare, Durham, North Carolina:

• aripiprazole tablets, 
• atorvastatin calcium tablets,
• buspirone hydrochloride tablets,
• clopidogrel tablets,
• daptomycin for injection,
• dofetilide capsules,
• doxazosin tablets,
• finasteride tablets,
• glimepiride tablets,
• glycopyrrolate injection,
• montelukast sodium tablets,
• phenylephrine hydrochloride injection,
• pirfenidone tablets,
• pravastatin sodium tablets,
• ropinirole tablets,
• rosuvastatin tablets,
• simvastatin tablets,
• succinylcholine chloride injection,
• tadalafil tablets, and 
• vigabatrin for oral solution.

The FDA Enforcement Report includes details for each medication recalled, including strengths, National Drug Codes, batch numbers, and expiration dates.

Accord Healthcare voluntarily initiated the recalls February 7, 2023. On March 2, 2023, the FDA designated them Class II. Per the classification, use of the recalled products may cause temporary or medically reversible adverse health consequences. A remote possibility of serious harm also exists.